Heim M
Psychiatr Neurol Med Psychol (Leipz). 1986 Dec;38(12):716-21.
The results of a standardized examination of 135 schizophrenics shows that the "depressive factor" is less pronounced during differential neuroleptic therapy (Clozapin, Haloperidol) and in the control group of schizophrenics receiving no drug treatment. This suggests that the depressive syndrome among schizophrenics is not manifested as a result of pharmaceutical action. The author proposes that neuroleptic therapy tailored to the patient can ameliorate the depressive syndrome observed in schizophrenics. Both psychoreactive and disease specific factors may play a role in the pathogenesis of depression among patients with this disease.
对135名精神分裂症患者进行标准化检查的结果显示，在使用不同的抗精神病药物治疗（氯氮平、氟哌啶醇）期间以及在未接受药物治疗的精神分裂症对照组中，“抑郁因子”并不那么明显。这表明精神分裂症患者的抑郁综合征并非药物作用所致。作者提出，根据患者情况量身定制的抗精神病药物治疗可以改善精神分裂症患者中观察到的抑郁综合征。心理反应性因素和疾病特异性因素可能在该疾病患者抑郁症的发病机制中都起作用。
